Revolutionizing Antibody Drug Conjugates With Precision and Innovation

About Us

Baylink Biosciences is focused on developing innovative antibody-drug conjugates (ADCs) for cancer treatment.

Our Technology

Baylink is transforming cancer therapy with breakthrough linker technology that enables innovative payloads, paving the way for next generation ADCs.

Strategy

To deliver transformative Antibody Drug Conjugate (ADC) medicines to patients with unmet medical needs.

Develop precision linkers to enable the best ADC design.

Lead ADC innovation by identifying novel payloads and best payload combinations in dual-payload-ADC.

About Us

Monoclonal_antibody_3D-effect_blue&green_edited.png

Technology

revolutionizing ADCs with precision and innovation

Breakthrough
Linker Technology

Baylink's novel linkers expand payload diversity, enabling use of hydrophobic drugs.

Unique design features are incorporated in the linker technology to reduce off-target effects and improve payload delivery to tumors.

Innovative
Payloads

Baylink is developing innovative payloads beyond TOP1i and MMAE payloads.

Protein degrader ADCs using molecular glues and PROTAC payloads offer new therapeutic approaches and are under development

at Baylink.

Addressing
Key Challenges

Baylink tackles critical issues: improving therapeutic index, expanding payload diversity, and overcoming resistance.

This drives the next wave

of precision ADCs.

NEWS

Get the latest updates from us

All articles

Baylink Biosciences to Present Its Novel Linker and Payload Technologies at 3rd ADC Linker & Conjugation Summit

Platform Reduces Non-Specific Uptake & Combats Resistance with Payload Diversity; Enables High DAR exatecan ADCs, Dual Payloads, & Degrader Antibody Conjugates PALO ALTO, CA, UNITED STATES, August 13, 2025 -- Baylink Biosciences, a biotechnology company pioneering next-generation antibody-drug conjugate (ADC) technologies, today announced it will present its proprietary linker and payload platforms at the 3rd ADC Linker & Conjugation Summit, taking place August 19–21, 2025, i

5 hours ago2 min read

Baylink Presents New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting

Preclinical results for lead ADC candidate BLB-101 for Claudin 6/9+ tumors supports potential best-in-class profile. Data presented demonstrating Baylink’s innovative ADC linker technology is overcoming major challenges in ADC development. PALO ALTO, Calif., April 25, 2025 -- Baylink Biosciences presented data from its Antibody Drug Conjugate portfolio at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL. The data presented for BLB-101, an ant

Apr 254 min read

Baylink To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting

Preclinical results for lead ADC candidate BLB-101 for Claudin 6/9+ tumors to be presented Data supporting the rationale for Baylink’s innovative ADC linker technology enabling delivery of degraders, dual payload antibody drug conjugates, and high drug to antibody ratio chemotherapy will be presented . PALO ALTO, Calif., April 15, 2025 -- Baylink Biosciences today announced that new preclinical data from its portfolio will be presented at the American Association for Cancer R

Apr 153 min read

Partner with us

Partnerships and collaborations are integral to driving innovation and delivering transformative therapies to patients. Baylink Biosciences is interested in exploring partnerships and collaborations across the antibody drug conjugate ecosystem. Please contact us to explore partnership and collaboration opportunities.

Revolutionizing Antibody Drug Conjugates With Precision and Innovation

About Us

Our Technology

Strategy

Technology

revolutionizing ADCs with precision and innovation

Breakthrough Linker Technology

Innovative Payloads

Addressing Key Challenges

NEWS

Baylink Biosciences to Present Its Novel Linker and Payload Technologies at 3rd ADC Linker & Conjugation Summit

Baylink Presents New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting

Baylink To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting

Partner with us

Breakthrough
Linker Technology

Innovative
Payloads

Addressing
Key Challenges